Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has today lauded the conclusions of a NHS England and the…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
One of the UK’s leading infectious disease biotech companies has announced a breakthrough in an antimicrobial resistance (AMR) program that…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched onto the minds of the British public – along with…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.
